• News
    • Latest news
    • News search
    • Health
    • Finance
    • Food
    • Career news
    • Content series
    • Focus areas
    • Try Devex Pro
  • Jobs
    • Job search
    • Post a job
    • Employer search
    • CV Writing
    • Upcoming career events
    • Try Career Account
  • Funding
    • Funding search
    • Funding news
  • Talent
    • Candidate search
    • Devex Talent Solutions
  • Events
    • Upcoming and past events
    • Partner on an event
  • Post a job
  • About
      • About us
      • Membership
      • Newsletters
      • Advertising partnerships
      • Devex Talent Solutions
      • Contact us
Join DevexSign in
Join DevexSign in

News

  • Latest news
  • News search
  • Health
  • Finance
  • Food
  • Career news
  • Content series
  • Focus areas
  • Try Devex Pro

Jobs

  • Job search
  • Post a job
  • Employer search
  • CV Writing
  • Upcoming career events
  • Try Career Account

Funding

  • Funding search
  • Funding news

Talent

  • Candidate search
  • Devex Talent Solutions

Events

  • Upcoming and past events
  • Partner on an event
Post a job

About

  • About us
  • Membership
  • Newsletters
  • Advertising partnerships
  • Devex Talent Solutions
  • Contact us
  • My Devex
  • Update my profile % complete
  • Account & privacy settings
  • My saved jobs
  • Manage newsletters
  • Support
  • Sign out
Latest newsNews searchHealthFinanceFoodCareer newsContent seriesFocus areasTry Devex Pro
    • News
    • Global Health

    Will infants finally have access to a highly effective HIV drug?

    Dolutegravir is one of the most effective and safest HIV medicines and is used by millions of adults and adolescents living with HIV in over 100 countries. But there’s no specific drug formulation for newborns.

    By Jenny Lei Ravelo // 11 March 2025

    Related Stories

    Despite 'chaos,' EGPAF maintains focus on ending pediatric AIDS
    Despite 'chaos,' EGPAF maintains focus on ending pediatric AIDS
    New partnerships bring price parity between lenacapavir and oral PrEP
    New partnerships bring price parity between lenacapavir and oral PrEP
    Ozempic generics are coming. But will low-income countries benefit?
    Ozempic generics are coming. But will low-income countries benefit?
    Guinea-Bissau still debating controversial US hepatitis B vaccine trial
    Guinea-Bissau still debating controversial US hepatitis B vaccine trial

    A new study has found the right dosage to administer a highly effective HIV treatment to newborns who are at risk of getting HIV.

    Dolutegravir is one of the most effective and safest HIV medicines, and the preferred drug treatment recommended by the World Health Organization. It has been in use for more than a decade as an HIV treatment by millions of adults and adolescents living with HIV in over 100 countries. But there’s no specific drug formulation for newborns.

    While many pregnant women have been taking dolutegravir for years to prevent mother-to-child transmission of HIV, this is not the case for everyone.

    This article is free to read - just register or sign in

    Access news, newsletters, events and more.

    Join usSign in
    • Global Health
    • Research
    • Social/Inclusive Development
    Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).

    About the author

    • Jenny Lei Ravelo

      Jenny Lei Ravelo@JennyLeiRavelo

      Jenny Lei Ravelo is a Devex Senior Reporter based in Manila. She covers global health, with a particular focus on the World Health Organization, and other development and humanitarian aid trends in Asia Pacific. Prior to Devex, she wrote for ABS-CBN, one of the largest broadcasting networks in the Philippines, and was a copy editor for various international scientific journals. She received her journalism degree from the University of Santo Tomas.

    Search for articles

    Related Stories

    Global healthRelated Stories - Despite 'chaos,' EGPAF maintains focus on ending pediatric AIDS

    Despite 'chaos,' EGPAF maintains focus on ending pediatric AIDS

    Global healthRelated Stories - New partnerships bring price parity between lenacapavir and oral PrEP

    New partnerships bring price parity between lenacapavir and oral PrEP

    Global HealthRelated Stories - Ozempic generics are coming. But will low-income countries benefit?

    Ozempic generics are coming. But will low-income countries benefit?

    Global HealthRelated Stories - Guinea-Bissau still debating controversial US hepatitis B vaccine trial

    Guinea-Bissau still debating controversial US hepatitis B vaccine trial

    Most Read

    • 1
      One year on: Is Africa’s surgical equity push delivering real change?
    • 2
      Ending HIV globally requires action in Eastern Europe and Central Asia
    • 3
      How to deliver results at scale for people and planet
    • 4
      What will it take to unlock private financing in a changing era?
    • 5
      US launches $4.5B platform inviting NGO support for bilateral health deals
    • News
    • Jobs
    • Funding
    • Talent
    • Events

    Devex is the media platform for the global development community.

    A social enterprise, we connect and inform over 1.3 million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people.

    • About us
    • Membership
    • Newsletters
    • Advertising partnerships
    • Devex Talent Solutions
    • Post a job
    • Careers at Devex
    • Contact us
    © Copyright 2000 - 2026 Devex|User Agreement|Privacy Statement